1. Pegylated-liposomes increase the efficacy of Idelalisib in lymphoma B-cells.
- Author
-
Maroni G, Tomassi E, Valenti D, Fernàndez-Busquets X, Pucci L, Levantini E, and Caddeo C
- Subjects
- Humans, Cell Line, Tumor, Cell Survival drug effects, Lymphoma, B-Cell drug therapy, Purines chemistry, Purines administration & dosage, Purines pharmacology, Quinazolinones chemistry, Quinazolinones administration & dosage, Quinazolinones pharmacology, Polyethylene Glycols chemistry, Liposomes, Antineoplastic Agents administration & dosage, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry
- Abstract
New drugs and technologies are continuously developed to improve the efficacy and minimize the critical side effects of cancer treatments. The present investigation focuses on the development of a liposomal formulation for Idelalisib, a small-molecule kinase inhibitor approved for the treatment of lymphoid malignancies. Idelalisib is a potent and selective antitumor agent, but it is not indicated nor recommended for first-line treatment due to fatal and serious toxicities. Herein, liposomes are proposed as a delivery tool to improve the therapeutic profile of Idelalisib. Specifically, PEGylated liposomes were prepared, and their physicochemical and technological features were investigated. Light-scattering spectroscopy and cryo-transmission electron microscopy revealed nanosized unilamellar vesicles, which were proved to be stable in storage and in simulated biological fluids. The cytotoxicity of the liposome formulation was investigated in a human non-Hodgkin's lymphoma B cell line. Idelalisib was able to induce death of tumor cells if delivered by the nanocarrier system at increased efficacy. These findings suggest that combining Idelalisib and nanotechnologies may be a powerful strategy to increase the antitumor efficacy of the drug., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF